- Home
- BBAI vs PRTA Comparison
BBAI vs PRTA Comparison
Compare BBAI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBAI
- PRTA
- Stock Information
- Founded
- BBAI 2020
- PRTA 2012
- Country
- BBAI United States
- PRTA Ireland
- Employees
- BBAI N/A
- PRTA N/A
- Industry
- BBAI EDP Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- BBAI Technology
- PRTA Health Care
- Exchange
- BBAI Nasdaq
- PRTA Nasdaq
- Market Cap
- BBAI 1.0B
- PRTA 809.8M
- IPO Year
- BBAI N/A
- PRTA N/A
- Fundamental
- Price
- BBAI $2.53
- PRTA $9.20
- Analyst Decision
- BBAI Strong Buy
- PRTA Buy
- Analyst Count
- BBAI 3
- PRTA 9
- Target Price
- BBAI $5.17
- PRTA $54.57
- AVG Volume (30 Days)
- BBAI 43.5M
- PRTA 572.3K
- Earning Date
- BBAI 05-01-2025
- PRTA 05-07-2025
- Dividend Yield
- BBAI N/A
- PRTA N/A
- EPS Growth
- BBAI N/A
- PRTA N/A
- EPS
- BBAI N/A
- PRTA N/A
- Revenue
- BBAI $158,236,000.00
- PRTA $135,157,000.00
- Revenue This Year
- BBAI $17.89
- PRTA N/A
- Revenue Next Year
- BBAI $12.87
- PRTA $131.71
- P/E Ratio
- BBAI N/A
- PRTA N/A
- Revenue Growth
- BBAI 1.98
- PRTA 47.92
- 52 Week Low
- BBAI $1.17
- PRTA $9.10
- 52 Week High
- BBAI $10.36
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- BBAI 36.56
- PRTA 26.58
- Support Level
- BBAI $2.41
- PRTA $9.30
- Resistance Level
- BBAI $2.98
- PRTA $10.45
- Average True Range (ATR)
- BBAI 0.30
- PRTA 0.81
- MACD
- BBAI 0.04
- PRTA -0.15
- Stochastic Oscillator
- BBAI 15.00
- PRTA 2.77
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a technology-led solutions organization, that provides both software and services to its customers. Its AI-powered decision intelligence solutions are leveraged in three markets; supply chains & logistics, autonomous systems, and cybersecurity. It operates in two segments; Cyber & Engineering segment and Analytics segment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).